Cagrilintide: Benefits, Dosage, and Weight Loss Potential Explained EASD e Learning Provided by leading diabetes academics Another win for brain centric obesity treatment approaches. Adding cagrilintide (an amylin analog) to semaglutide (a GLP 1 analog) enhances weight loss. 17.1% weight loss over 20 wk at highest dose, with weight still Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online